Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation
Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park
Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park
View: Text | PDF
Research Article Neuroscience Vascular biology

Endothelial oncogenic KRAS mutation drives the dynamics of microglia and macrophages in brain arteriovenous malformation

  • Text
  • PDF
Abstract

Mutation of KRAS in endothelial cells (KRAS-ECs) leads to intracerebral hemorrhage (ICH) in brain arteriovenous malformation (bAVM), resulting in severe disabilities or even death. However, it is unclear what causes this hemorrhagic conversion of bAVMs. Here, using a locally established, clinically relevant sporadic bAVM mouse model, created by overexpressing mutant KRAS (KRASG12V) in brain ECs, we demonstrate that KRAS-ECs act as trigger for activation of microglia (MG) and infiltration of macrophages (Mϕ). Using a 3-dimensional immunostaining approach with cleared human and mouse bAVM tissues, we demonstrate an abundance of MG/Mϕ around the bAVM nidus. The presence of MG/Mϕ was correlated to the blood-brain barrier leakage in bAVM areas. Time-lapsed intravital imaging in Cx3cr1-gfp;Ccr2-rfp reporter mice demonstrated the dynamic activation of MG and infiltration of Mϕ toward mutant KRASG12V–modified dysplastic vessels. Importantly, a time-course analysis showed that these activated MG and infiltrated Mϕ are present around the bAVMs prior to hemorrhagic conversion, and controlled depletion of MG/Mϕ reduced ICH incidence in bAVMs. Inhibition of MG/Mϕ with long-term minocycline treatment attenuated the incidence of ICHs around bAVMs. Our study indicates that MG/Mϕ are involved in destabilization of KRASG12V-induced bAVM, leading to hemorrhagic conversion/ICH. Thus, modulation of MG/Mϕ may reduce ICH risk in patients with bAVM.

Authors

Hyejin Park, Jung-Eun Park, Bridger H. Freeman, Bosco Seong Kyu Yang, Shun-Ming Ting, Alexander K. Suh, Jude P.J. Savarraj, Shuning Huang, Jakob Körbelin, Huimahn Alex Choi, Sean P. Marrelli, Jaroslaw Aronowski, Peng Roc Chen, Eunhee Kim, Eun S. Park

×

Figure 4

Early-stage–activated MG are responsible for the ICH occurrence in KRASG12V/bEC mice.

Options: View larger image (or click on image) Download as PowerPoint
Early-stage–activated MG are responsible for the ICH occurrence in KRASG...
(A) Brains were harvested 4 weeks after AAV-BR1-KRASG12V or AAV-BR1-eGFP (control) injection. (B) Representative immunofluorescence images showing robust Iba1+ MG and BSA-647 leakage in both ruptured (Ter-119hi) and unruptured (Ter-119lo) bAVM territory. Scale bar: 50 μm. (C–E) Bar graphs quantifying Iba1+ cell numbers (C) and area of BSA-647 leakage (D) in ruptured (Ter-119hi) and unruptured (Ter-119lo) bAVM territory compared with intact. Note that the BSA-647 leakage is correlated to the presence of Iba1+ cells (E). One-way ANOVA and Tukey’s multiple comparisons test and unpaired, 2-tailed t test. *P < 0.05; ***P < 0.001; ****P < 0.0001. NS, not significant. Each dot indicates a randomly selected ROI (n = 12–25) obtained from mice (n = 6 per group). (F) Bar graphs quantifying the increased mRNA levels of IL6, MMP2, TMEM119, or CSF1R in the dissected olfactory bulb (OB). Unpaired t test. *P < 0.05; **P < 0.01. Each dot indicates an individual mouse (n = 5 per group). The scheme was created with BioRender.com. (G) Clodronate liposomes (CLs) or control liposomes (Encapsome) were administered 1 week after AAV-BR1-KRASG12V injection. Brains were harvested 2 weeks after AAV-BR1-KRASG12V injection. (H) Representative immunofluorescence images showing reduced Iba1+ cells and Ter-119+ RBCs in CL-treated KRASG12V/bEC mice compared with control liposome–treated (Encapsome-treated) mice. Scale bar: 25 μm. (I and J) Bar graphs quantifying Ter-119+ RBCs in the parenchyma (I) and Iba1+ cells (J) in bAVM territories. Unpaired, 2-tailed t tests. ***P < 0.001, ****P < 0.0001. Each dot indicates a randomly selected ROI (n = 16) obtained from mice (n = 6 and 5 per group).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts